Rufinamide

FDA Approved: * May 16, 2016
Pharm Company: * ROXANE
Category: Anticonvulsant

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome[2] and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. Rufinamide was approved by the US Food and Drug Administration (FDA) on November 14, 2008, as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children four ye... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rufinamide 200 mg Oral Tablet, Film Coated
NDC: 0054-0425
Labeler:
Hikma Pharmaceuticals USA Inc.
Rufinamide 400 mg Oral Tablet, Film Coated
NDC: 0054-0426
Labeler:
Hikma Pharmaceuticals USA Inc.
Rufinamide 40 mg/ml Oral Suspension
NDC: 0054-0528
Labeler:
Hikma Pharmaceuticals USA Inc.
Rufinamide 200 mg Oral Tablet, Film Coated
NDC: 0378-2330
Labeler:
Mylan Pharmaceuticals Inc.
Rufinamide 400 mg Oral Tablet, Film Coated
NDC: 0378-2331
Labeler:
Mylan Pharmaceuticals Inc.
Rufinamide 200 mg Oral Tablet, Film Coated
NDC: 31722-598
Labeler:
Camber Pharmaceuticals, Inc.
Rufinamide 400 mg Oral Tablet, Film Coated
NDC: 31722-599
Labeler:
Camber Pharmaceuticals, Inc.
Rufinamide 40 mg/ml Oral Suspension
NDC: 59651-563
Labeler:
Aurobindo Pharma Limited
Rufinamide 400 mg Oral Tablet, Film Coated
NDC: 60687-643
Labeler:
American Health Packaging
Rufinamide 40 mg/ml Oral Suspension
NDC: 67877-673
Labeler:
Ascend Laboratories, LLC

Related Brands

Drugs with the same active ingredients